沙利鲁单抗联合或不联合传统合成改善病情抗风湿药治疗类风湿关节炎的长期安全性与有效性
该分析纳入六项随机试验后进入EXTEND和MONARCH开放标签延展期的类风湿关节炎患者,评估沙利鲁单抗联合或不联合传统合成改善病情抗风湿药的长期安全性、免疫原性及疗效。结果显示未发现新的安全性信号,中性粒细胞减少最常见但不增加感染风险,临床与健康相关生活质量改善在开放标签评估期间得以维持或进一步提高。
要点
- 沙利鲁单抗联合或不联合传统合成改善病情抗风湿药长期治疗未发现新的安全性发现。
- 中性粒细胞减少为最常见不良事件,但与感染发生率增加无关,多数在治疗中恢复正常。
- 免疫原性低,且与超敏反应或因疗效缺乏或丧失而停药无关。
核心结论
- 沙利鲁单抗联合或不联合传统合成改善病情抗风湿药长期治疗类风湿关节炎未发现新的安全性发现,疗效与健康相关生活质量在开放标签评估期间得以维持或进一步提高。
研究设计与样本
- 分析纳入六项随机试验后进入EXTEND和MONARCH开放标签延展期的患者,评估沙利鲁单抗200 mg每2周一次给药至少264周至最多516周(EXTEND)或276周(MONARCH OLE)的安全性与有效性。
主要发现
- 沙利鲁单抗单药组(n=111)、延续组(n=165)和切换组(n=155)接受沙利鲁单抗单药治疗,沙利鲁单抗联合传统合成改善病情抗风湿药组(n=1910)接受联合治疗。
- 发生一种或以上治疗中出现的不良事件发生率分别为单药组126、联合组169、延续组159和切换组159事件/100患者年。
- 中性粒细胞减少为最常见不良事件,与感染发生率增加无关,多数病例在治疗中恢复正常。
- 特殊关注的不良事件如恶性肿瘤、主要不良心血管事件、静脉血栓栓塞和胃肠道穿孔罕见。
- 免疫原性低,且与超敏反应或因疗效缺乏或丧失而停药无关;初始盲法试验中观察到的临床体征症状和健康相关生活质量改善在整个开放标签评估期间得以维持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term safety and efficacy of sarilumab with/without conventional synthetic (cs)DMARDs in RA. METHODS: The analyses evaluated two open-label extensions (OLEs): EXTEND and MONARCH OLE, which included patients from six randomized trials. Patients received sarilumab 200 mg once every 2 weeks (q2w) for at least 264 weeks up to 516 weeks (EXTEND: Sarilumab Monotherapy and Sarilumab + csDMARD groups) or for 276 weeks (MONARCH OLE: Continuation and Switch groups). Primary endpoints included safety, immunogenicity and changes in laboratory parameters. Secondary endpoints included clinical signs and symptoms along with health-related quality-of-life (HRQOL) questionnaires. RESULTS: The Sarilumab Monotherapy (n = 111), Continuation (n = 165) and Switch (n = 155) groups received sarilumab monotherapy, while the Sarilumab + csDMARD group (n = 1910) received sarilumab in combination with csDMARDs. Incidence of one or more treatment-emergent adverse events was 126 (Sarilumab Monotherapy group), 169 (Sarilumab + csDMARD group), 159 (Continuation group) and 159 (Switch group) events/100 patient-years. Neutropenia was the most common adverse event. Neutropenia was not associated with an increased incidence of infections. Most neutropenia cases normalized on-treatment. Adverse events of special interests, such as malignancies, major adverse cardiovascular events, venous thromboembolism and gastrointestinal perforations, were rare. Immunogenicity was low and not associated with hypersensitivity reactions or discontinuations due to lack or loss of efficacy. Improvements in clinical signs and symptoms and HRQOL, observed during the initial blinded trials, were maintained throughout the OLE assessment period. CONCLUSIONS: Long-term sarilumab treatment with/without csDMARDs in patients with RA revealed no new safety findings. Efficacy and HRQOL were maintained or further increased over the open-label assessment period. TRIAL REGISTRATION: EXTEND, ClinicalTrials.gov, https://www.clinicaltrials.gov/ct2/show/NCT01146652, NCT01146652; MONARCH OLE, ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02332590, NCT02332590.
引用
- Burmester GR, Strand V, Kivitz AJ, et al. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 36727470. doi:10.1093/rheumatology/kead062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。